Virtu Financial’s Anixa Biosciences ANIX Stock Holding History

Virtu Financial’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,759	Closed	-$161K	–	1598
2025 Q4	$161K	Buy	+51,759	New	+$212K	0.01%	1088
2024 Q4	–	Sell	-10,786	Closed	-$34K	–	1511
2024 Q3	$34K	Buy	+10,786	New	+$33.2K	﹤0.01%	1059
2024 Q2	–	Sell	-16,156	Closed	-$50K	–	1274
2024 Q1	$50K	Buy	16,156 +5,183	+47%	+$20.7K	﹤0.01%	1026
2023 Q4	$43K	Buy	+10,973	New	+$37K	﹤0.01%	1198
2023 Q2	–	Sell	-18,409	Closed	-$79K	–	1483
2023 Q1	$79K	Buy	+18,409	New	+$80.6K	0.01%	1025
2022 Q3	–	Sell	-14,738	Closed	-$45K	–	1696
2022 Q2	$45K	Buy	+14,738	New	+$46.5K	﹤0.01%	1148
2022 Q1	–	Sell	-28,201	Closed	-$84K	–	1471
2021 Q4	$84K	Buy	28,201 +16,407	+139%	+$66.3K	0.01%	1197
2021 Q3	$56K	Buy	+11,794	New	+$53.2K	﹤0.01%	1253
2018 Q2	–	Sell	-26,201	Closed	-$101K	–	1954
2018 Q1	$101K	Buy	+26,201	New	+$101K	0.01%	1573
2017 Q4	–	Sell	-61,536	Closed	-$162K	–	2334
2017 Q3	$162K	Buy	+61,536	New	+$67.7K	0.01%	1935

Other funds holding ANIX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial's ANIX Position: Q1 2026 in Review

Virtu Financial sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 51,759 shares — an estimated $161K sold.

Virtu Financial first reported a position in ANIX in Q3 2017 and held it in 10 quarters. The position peaked at $162K in Q3 2017. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

Virtu Financial reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
Virtu Financial sold 51,759 Anixa Biosciences shares in Q1 2026, an estimated $161K.
Virtu Financial first reported a position in Anixa Biosciences in Q3 2017 and held it in 10 quarters.
Virtu Financial's Anixa Biosciences position peaked at $162K in Q3 2017.
60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.